LFCR logo

LFCR
Lifecore Biomedical Inc

645
Mkt Cap
$256.64M
Volume
238,276.00
52W High
$8.85
52W Low
$4.76
PE Ratio
-5.25
LFCR Fundamentals
Price
$6.85
Prev Close
$6.62
Open
$6.59
50D MA
$7.12
Beta
1.74
Avg. Volume
173,807.52
EPS (Annual)
-$1.27
P/B
189.86
Rev/Employee
$317,406.40
Loading...
Loading...
News
all
press releases
Lifecore Biomedical (NASDAQ:LFCR) Releases Earnings Results, Beats Estimates By $0.01 EPS
Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of +3.33% and +16.60%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -5.43% and +4.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Lifecore Biomedical (LFCR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?
Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·2mo ago
News Placeholder
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of -11.11% and +1.96%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
What to Expect in the Markets This Week
Coming up: New Year's Day holiday, pending home sales, home price index, manufacturing PMI, Fed speakersUCG / Contributor / Getty ImagesKey TakeawaysStock and bond markets will be closed on Wednesday...
Investopedia Headlines·11mo ago
News Placeholder
LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. (Lifecore or the Company) (NASDAQ: LFCR) for...
Business Wire·1y ago
News Placeholder
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Lifecore...
Business Wire·1y ago

Latest LFCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.